Amedisys, Inc. (NASDAQ:AMED) Stock Position Raised by Versant Capital Management Inc

Versant Capital Management Inc lifted its position in Amedisys, Inc. (NASDAQ:AMED) by 68.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 450 shares of the health services provider’s stock after buying an additional 183 shares during the quarter. Versant Capital Management Inc’s holdings in Amedisys were worth $41,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV bought a new stake in Amedisys in the third quarter worth approximately $63,000. Signaturefd LLC lifted its stake in shares of Amedisys by 20.9% in the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after purchasing an additional 236 shares during the last quarter. CWM LLC boosted its holdings in Amedisys by 14.5% in the third quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after purchasing an additional 277 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in Amedisys during the third quarter worth $243,000. Finally, Intech Investment Management LLC bought a new position in Amedisys during the second quarter valued at about $280,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $91.79 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market capitalization of $3.01 billion, a P/E ratio of 36.42, a P/E/G ratio of 1.84 and a beta of 0.72. The business has a 50-day moving average of $89.74 and a two-hundred day moving average of $94.44. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. During the same period in the prior year, the business earned $0.98 EPS. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. On average, equities research analysts predict that Amedisys, Inc. will post 4.45 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.